Combination ATR and PARP Inhibitor (CAPRI): A phase 2 study of ceralasertib plus olaparib in patients with recurrent, platinum-resistant epithelial ovarian cancer

著者: Payal D. Shah, Stephanie L. Wethington, Cheyenne Pagan, Nawar Latif, János L. Tanyi, Lainie P. Martin, Mark A. Morgan, Robert A. Burger, Ashley Haggerty, Haley Zarrin, Diego Rodriguez, Susan M. Domchek, Ronny Drapkin, Ie−Ming Shih, Simon A. Smith, Emma Dean, Stéphanie Gaillard, Deborah K. Armstrong, Drew A. Torigian, Wei‐Ting Hwang, Robert Giuntoli, Fiona Simpkins - Gynecologic Oncology 2021 被引用: 117